JPWO2021007465A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021007465A5
JPWO2021007465A5 JP2022502022A JP2022502022A JPWO2021007465A5 JP WO2021007465 A5 JPWO2021007465 A5 JP WO2021007465A5 JP 2022502022 A JP2022502022 A JP 2022502022A JP 2022502022 A JP2022502022 A JP 2022502022A JP WO2021007465 A5 JPWO2021007465 A5 JP WO2021007465A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
nucleic acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545055A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041473 external-priority patent/WO2021007465A2/fr
Publication of JP2022545055A publication Critical patent/JP2022545055A/ja
Publication of JPWO2021007465A5 publication Critical patent/JPWO2021007465A5/ja
Pending legal-status Critical Current

Links

JP2022502022A 2019-07-09 2020-07-09 PRDM14タンパク質の発現をダウンレギュレートする標的化siRNA製剤を使用する癌処置 Pending JP2022545055A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872084P 2019-07-09 2019-07-09
US62/872,084 2019-07-09
PCT/US2020/041473 WO2021007465A2 (fr) 2019-07-09 2020-07-09 Traitement du cancer faisant appel à des formulations pharmaceutiques d'parni ciblées pour réguler à la baisse l'expression de la protéine prdm14

Publications (2)

Publication Number Publication Date
JP2022545055A JP2022545055A (ja) 2022-10-25
JPWO2021007465A5 true JPWO2021007465A5 (fr) 2023-07-19

Family

ID=74115310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502022A Pending JP2022545055A (ja) 2019-07-09 2020-07-09 PRDM14タンパク質の発現をダウンレギュレートする標的化siRNA製剤を使用する癌処置

Country Status (5)

Country Link
US (1) US20220267775A1 (fr)
EP (1) EP3996684A4 (fr)
JP (1) JP2022545055A (fr)
CN (1) CN114727958B (fr)
WO (1) WO2021007465A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113421A (zh) 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗
CN113616593A (zh) * 2021-08-23 2021-11-09 嘉兴学院 一种纳米靶向聚合物胶束在制备靶向给药系统中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5219818B2 (ja) * 2006-09-27 2013-06-26 今井浩三 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット
WO2011050178A2 (fr) * 2009-10-21 2011-04-28 Lonnie Bookbinder Agents thérapeutiques de modulation ciblée de gènes ou protéines prdm
EP2571987B1 (fr) * 2010-05-21 2017-03-01 Peptimed, Inc. Réactifs pour le traitement du cancer
WO2012061443A2 (fr) * 2010-11-01 2012-05-10 NanoOncology, Inc. Compositions d'un système à base de peptides pour le ciblage spécifique de cellules
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
EP3052521A1 (fr) * 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
WO2016065273A1 (fr) * 2014-10-24 2016-04-28 The University Of Chicago Domaines de protéines thermo-inductibles à auto-assemblage

Similar Documents

Publication Publication Date Title
ES2197885T3 (es) Uso de inhibidores csf-1.
US20230031703A1 (en) Stabilized hnf4a sarna compositions and methods of use
US20240018519A1 (en) Stabilized saRNA Compositions and Methods of Use
MX2011000227A (es) Composiciones y metodos para inhibir la expresion de genes del receptor de factor de crecimiento por transformacion-beta.
CA2692155A1 (fr) Compositions comprenant un arnsi de egfr humain et leurs procedes d'utilisation
KR20100131509A (ko) Rna 간섭 효과가 높은 2본쇄 지질 수식 rna
JP2010502230A (ja) Sirnaおよび製造方法
CN107530439B (zh) 用于治疗癌症的对人抗原R表达的siRNA抑制
JP6033218B2 (ja) がんを治療するための試薬および方法
US20220281911A1 (en) Oligonucleotide conjugate compositions and methods of use
ES2363500T3 (es) Arn interferente para el gen znfn3a1 como método para inhibir el crecimiento de células cancerosas.
WO2012173994A2 (fr) Formulations de modification de phase de charges utiles d'acide nucléique
JP2022545055A (ja) PRDM14タンパク質の発現をダウンレギュレートする標的化siRNA製剤を使用する癌処置
JPWO2021007465A5 (fr)
JP3289912B2 (ja) ポリアミノ酸オリゴヌクレオチドキャリヤー
WO2011111874A1 (fr) Arn du type en forme d'haltère et à perméation de membrane cellulaire et son procédé de fabrication
KR20240040112A (ko) 방법
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
US20150329857A1 (en) Rna interference to activate stem cells
EP2064328A2 (fr) Sensibilisation des cellules de cancer à la thérapie en utilisant le sina visant des gènes des régions 1p et 19q chromosomiques
JPWO2019181305A1 (ja) snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤
WO2014169087A2 (fr) Traitement de l'atrophie musculaire spinale proximale
KR101595152B1 (ko) Tctp-ptd를 포함하는 유전자 전달체
US11655474B2 (en) Suppression of pathological angiogenesis by inhibition of NR2F6
US20240150764A1 (en) Therapeutic splice-switching oligonucleotides for cancer